MedTrace Logo

Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer

NCT00004086 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2009-06-09

No results posted yet for this study

Summary

RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and either kill them or deliver cancer killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody plus combination chemotherapy and peripheral stem cell transplantation in treating patients who have recurrent or B-cell cancer.

Conditions

Interventions

BIOLOGICAL

filgrastim

DRUG

cisplatin

DRUG

cytarabine

DRUG

etoposide

DRUG

ifosfamide

PROCEDURE

autologous bone marrow transplantation

PROCEDURE

peripheral blood stem cell transplantation

RADIATION

indium In 111 LL2 IgG

RADIATION

yttrium Y 90 epratuzumab

Sponsors & Collaborators

  • Garden State Cancer Center at the Center for Molecular Medicine and Immunology

    lead OTHER

Principal Investigators

  • Jack D. Burton, MD · Garden State Cancer Center at the Center for Molecular Medicine and Immunology

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004086 on ClinicalTrials.gov